These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29207937)

  • 1. A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia.
    Johannesmeyer HJ; Seifert CF
    J Oncol Pharm Pract; 2019 Apr; 25(3):535-543. PubMed ID: 29207937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
    Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
    Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to antibiotics and outcomes in cancer patients with febrile neutropenia.
    Perron T; Emara M; Ahmed S
    BMC Health Serv Res; 2014 Apr; 14():162. PubMed ID: 24716604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.
    Butts AR; Bachmeier CC; Dressler EV; Liu M; Cowden A; Talbert J; Adams VR
    J Oncol Pharm Pract; 2017 Jun; 23(4):278-283. PubMed ID: 28077045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: Is there room for improvement?
    Jansma B; Vakkalanka P; Talan DA; Negaard B; Faine BA
    J Oncol Pharm Pract; 2020 Sep; 26(6):1382-1389. PubMed ID: 31955667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
    Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
    Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia.
    Walker ST; Grigg S; Kirkpatrick C; Urbancic K; Cohen E; Grigg A; Trubiano J
    Support Care Cancer; 2020 Sep; 28(9):4337-4343. PubMed ID: 31912358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.
    Keng MK; Thallner EA; Elson P; Ajon C; Sekeres J; Wenzell CM; Seastone DJ; Gallagher EM; Weber CM; Earl MA; Mukherjee S; Pohlman B; Cober E; Foster VB; Yuhas J; Kalaycio ME; Bolwell BJ; Sekeres MA
    J Oncol Pract; 2015 Nov; 11(6):450-5. PubMed ID: 26220930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia.
    Haiduc M; Patel M; Walsh TL; Moffa MA; Bremmer DN
    J Oncol Pharm Pract; 2021 Mar; 27(2):297-304. PubMed ID: 32316878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
    Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
    J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department.
    Lynn JJ; Chen KF; Weng YM; Chiu TF
    Hematol Oncol; 2013 Dec; 31(4):189-96. PubMed ID: 23303687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of empiric antibiotic de-escalation in febrile neutropenia.
    Kroll AL; Corrigan PA; Patel S; Hawks KG
    J Oncol Pharm Pract; 2016 Oct; 22(5):696-701. PubMed ID: 26227319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
    Nguyen M; Jacobson T; Torres J; Wann A
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of an evidence-based order set to impact initial antibiotic time intervals in adult febrile neutropenia.
    Best JT; Frith K; Anderson F; Rapp CG; Rioux L; Ciccarello C
    Oncol Nurs Forum; 2011 Nov; 38(6):661-8. PubMed ID: 22037329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.
    Fehér C; Rovira M; Soriano A; Esteve J; Martínez JA; Marco F; Carreras E; Martínez C; Fernández-Avilés F; Suárez-Lledó M; Mensa J
    J Antimicrob Chemother; 2014 Sep; 69(9):2556-62. PubMed ID: 24855125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.